Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events
22. Mai 2018 02:00 ET
|
Spark Therapeutics, Inc.
Annualized bleeding rate (ABR) for all 15 participants was reduced by 98 percent, while annualized infusion rate (AIR) was reduced by 99 percent as of the May 7, 2018 data cutoff Range of...
Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress
08. Mai 2018 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, May 08, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
Spark Therapeutics to Host Conference Call on Tuesday, May 8 at 8:30 a.m. ET to Discuss First Quarter Results and Recent Business Highlights
01. Mai 2018 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, May 01, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a...
Spark Therapeutics Sells Priority Review Voucher for $110 Million
30. April 2018 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, April 30, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics to Participate in Multiple Conferences in March
23. Februar 2018 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics Reports 2017 Financial Results and Recent Business Progress
20. Februar 2018 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
Spark Therapeutics to Host Conference Call on Tuesday, Feb. 20 at 8:30 a.m. ET to Discuss 2017 Results and Recent Business Highlights
13. Februar 2018 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a...
Spark Therapeutics to Participate in Multiple Conferences in February
05. Februar 2018 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics Enters into a Licensing and Supply Agreement for Investigational Voretigene Neparvovec Outside the U.S.
24. Januar 2018 16:00 ET
|
Spark Therapeutics, Inc.
Novartis Pharmaceuticals will commercialize investigational voretigene neparvovec when and if approved in Europe and all other markets outside the U.S.; Spark Therapeutics retains U.S. commercial...
Spark Therapeutics Announces Addition of Robert J. Perez to Board of Directors
04. Januar 2018 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...